Copanlisib is a potent and selective inhibitor of phosphatidylinositol 3-kinase (PI3K) that is used in the treatment of various cancers. Copanlisib impurities refer to any unwanted substances that may be present in copanlisib, such as residual solvents, starting materials, or by-products of the synthesis process. The presence of these impurities can affect the purity and quality of copanlisib and may also have an impact on its efficacy and safety. Therefore, it is important to carefully monitor and control the levels of copanlisib impurities during the manufacturing process to ensure the highest standards of product quality and patient safety.